Staphylococcal Infections Clinical Trial
— SoTiClinOfficial title:
Adjunctive Clindamycin Versus Standard of Care for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled, Open-label Superiority Phase 4 Trial
This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | July 31, 2024 |
Est. primary completion date | March 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adults (age =18 years); 2. Need for a treatment (incision/drainage ± antibiotic treatment po or iv) of an SSTI; 3. S. aureus causing SSTI identified from at least one clinical specimen (including isolation in polymicrobial cultures if S. aureus is considered to be the leading pathogen); 4. Onset of symptoms within the last 4 weeks; 5. Randomisation possible within 72 hours from collection of the initial culture 6. Ability to conduct the follow-up visits either during admission or at home 7. Initial culture collected within 48 hours of hospital admission 8. Willingness to participate in the study. Exclusion Criteria 1. Previous allergic reaction to clindamycin 2. Previous antibiotic-associated diarrhea 3. Previous study participation 4. Pregnancy as confirmed by a beta-HCG rapid test. 5. Started treatment with clindamycin prior to clinic presentation; 6. Documented systemic antibiotic treatment within the previous 14 days 7. Co-administration of other protein synthesis inhibitors (e.g. macrolides, rifampicin, linezolid, aminoglycosides, tetracyclines, chloramphenicol); 8. Co-administration of toxin inducers (trimethoprim-sulfamethoxazole) 9. Severe illness (patient expected to die in the following 24 hrs); 10. Chronically infected wounds (>4 weeks of symptoms); 11. Infections associated with any of the following (due to mixed infection): a) Human or animal bites;b) Prosthetic or implantable devices; c) Decubitus ulcers; d) Diabetic foot ulcers, infected ulcers secondary to peripheral artery disease, chronic venous insufficiency; e) Suspected Buruli ulcer; f) Infected burns. 12. Hospital-acquired infection including post-surgical site infections |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Frieder Schaumburg |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical cure at follow-up 7 days | Proportion of patients with clinical cure defined as the absence of clinical failure | Day 7 | |
Secondary | Change in inflammatory markers under therapy | Change in mean C-reactive protein level | from baseline to Day 3 and from baseline to Day 7 | |
Secondary | Time to symptom resolution | Time to resolution of symptoms | during follow-up up to day 14 | |
Secondary | Occurence of adverse events | Proportion of patients with adverse events (of any kind) and of adverse events that required treatment discontinuation or change in drugs used | anytime during follow-up (to day 14) | |
Secondary | Microbiological failure | Proportion of microbiological treatment failure (culture of S. aureus in relevant materials) on Day 3 and Day 7; | during follow-up day 3 and day 7 | |
Secondary | Clostridioides difficile associated diarrhoea | Proportion with Clostridioides difficile associated diarrhoea | during follow-up, up to day 14 | |
Secondary | Recurrent infections | Proportion of recurrent infections during a passive follow up of 6 months | 6 months passive follow-up (participant re-presents to clinic) | |
Secondary | Clinical cure at follow-up 14 days | Proportion of patients with clinical cure defined as the absence of clinical failure | Day 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01447407 -
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
|
Phase 1 | |
Recruiting |
NCT00518076 -
Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant
|
N/A | |
Completed |
NCT01324440 -
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
|
Phase 1 | |
Completed |
NCT00501150 -
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
|
N/A | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00063089 -
Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever
|
Phase 1/Phase 2 | |
Completed |
NCT00175370 -
Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus
|
N/A | |
Recruiting |
NCT03456544 -
Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
|
||
Completed |
NCT02557568 -
Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne
|
N/A | |
Terminated |
NCT01196169 -
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
|
Phase 4 | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Completed |
NCT02971657 -
Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients` Clinical Outcome in Orthopedic Device Related Bone Infections
|
N/A | |
Completed |
NCT02640937 -
Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections
|
N/A | |
Completed |
NCT00303069 -
V710 First-In-Man (FIM) Study (V710-001)
|
Phase 1 | |
Completed |
NCT00156377 -
Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections
|
Phase 4 | |
Completed |
NCT00631566 -
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
|
N/A | |
Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A | |
Completed |
NCT02782078 -
Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections
|
N/A | |
Completed |
NCT00859677 -
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
|
||
Completed |
NCT00211900 -
Evaluation of Manufacturing Lot of StaphVAX
|
Phase 3 |